| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0959-8049(98)00278-0 |
| P698 | PubMed publication ID | 10211101 |
| P2093 | author name string | H Yamazaki | |
| M Nakamura | |||
| H Sato | |||
| Y Fukushima | |||
| Y Ueyama | |||
| T Tokunaga | |||
| T Tsuchida | |||
| H Kijima | |||
| N Tamaoki | |||
| M Tomisawa | |||
| Y Oshika | |||
| P2860 | cites work | Vascular endothelial growth factor is a secreted angiogenic mitogen | Q28646475 |
| Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid | Q29617640 | ||
| The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. | Q33301664 | ||
| Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma | Q34570747 | ||
| Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. | Q35823939 | ||
| Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer | Q36292182 | ||
| Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors | Q37370535 | ||
| The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. | Q40241912 | ||
| VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells | Q41346007 | ||
| Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. | Q52553091 | ||
| Vascular permeability factor, an endothelial cell mitogen related to PDGF | Q69116052 | ||
| The value of histoquantitative measurements in prognostic assessment of renal adenocarcinoma | Q70498389 | ||
| Tumor angiogenesis as a predictor of recurrence in gastric carcinoma | Q71671979 | ||
| Renal cell carcinoma in New Zealand: a national survival study | Q72308380 | ||
| Prognosis after nephrectomy for renal cell carcinoma | Q72398630 | ||
| Vascular endothelial growth factor expression is increased in renal cell carcinoma | Q73273065 | ||
| Expression of cell-associated isoform of vascular endothelial growth factor 189 and its prognostic relevance in non-small cell lung cancer | Q74209411 | ||
| Is xenotransplantability of human colon cancers in SCID mice affected by angiogenic factors? | Q74302761 | ||
| P433 | issue | 1 | |
| P921 | main subject | renal cell carcinoma | Q1164529 |
| P304 | page(s) | 133-137 | |
| P577 | publication date | 1999-01-01 | |
| P1433 | published in | European Journal of Cancer | Q332260 |
| P1476 | title | Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma | |
| P478 | volume | 35 |
| Q79443419 | A comparison of the vascular density of VEGF expression with microvascular density determined with CD34 and CD31 staining and conventional prognostic markers in renal cell carcinoma |
| Q33682981 | Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy. |
| Q24814890 | Alteration of protein expression pattern of vascular endothelial growth factor (VEGF) from soluble to cell-associated isoform during tumourigenesis |
| Q31126032 | Analysis of various potential prognostic markers and survival data in clear cell renal cell carcinoma |
| Q37101283 | Angiogenesis and its therapeutic opportunities |
| Q73112514 | Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma |
| Q43823716 | Clinical significance of urinary vascular endothelial growth factor and microvessel density in patients with renal cell carcinoma |
| Q36452714 | Current status and perspective of antiangiogenic therapy for cancer: urinary cancer |
| Q28363910 | Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis |
| Q44567628 | Differential expression of vascular endothelial growth factor-A isoforms at different stages of melanoma progression |
| Q29622818 | Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer |
| Q34261539 | Do anti-angiogenic VEGF (VEGFxxxb) isoforms exist? A cautionary tale |
| Q33510275 | Establishment of canine hemangiosarcoma xenograft models expressing endothelial growth factors, their receptors, and angiogenesis-associated homeobox genes |
| Q94585822 | Expression of HIF-1α and VEGF in feline mammary gland carcinomas: association with pathological characteristics and clinical outcomes |
| Q33202253 | Expression of a flt-4 (VEGFR3) splicing variant in primary human prostate tumors. VEGF D and flt-4t(Delta773-1081) overexpression is diagnostic for sentinel lymph node metastasis |
| Q45886265 | Expression of angiostatin cDNA in a murine renal cell carcinoma suppresses tumor growth in vivo |
| Q73853975 | Expression of vascular endothelial growth factor in renal cell carcinoma and the relation to angiogenesis and p53 protein expression |
| Q35746653 | Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas |
| Q35748149 | Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. |
| Q28365033 | Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization |
| Q40372513 | Influence of Exposure to Chronic Persistent Low-Dose Ionizing Radiation on the Tumor Biology of Clear-Cell Renal-Cell Carcinoma. An Immunohistochemical and Morphometric Study of Angiogenesis and Vascular Related Factors |
| Q36528227 | Inhibiting colorectal carcinoma growth and metastasis by blocking the expression of VEGF using RNA interference |
| Q36624170 | Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor |
| Q36003288 | Lentivirus-mediated RNAi knockdown of VEGFA in RKO colorectal cancer cells decreases tumor formation and growth in vitro and in vivo |
| Q64240759 | Metastatic renal cell carcinoma regains sensitivity to tyrosine kinase inhibitor after nivolumab treatment: A case report |
| Q53442702 | Molecular biomarkers for advanced renal cell carcinoma: implications for prognosis and therapy. |
| Q34089123 | Molecular diversity of VEGF-A as a regulator of its biological activity. |
| Q34157370 | Neuropilin 1 and neuropilin 2 co-expression is significantly correlated with increased vascularity and poor prognosis in nonsmall cell lung carcinoma |
| Q88159233 | Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab |
| Q36644517 | Periodate-treated, non-anticoagulant heparin-carrying polystyrene (NAC-HCPS) affects angiogenesis and inhibits subcutaneous induced tumour growth and metastasis to the lung |
| Q37633008 | Potential use of circulating endothelial cells as a biomarker of renal cell carcinoma |
| Q36942659 | Promoting melanoma growth and metastasis by enhancing VEGF expression |
| Q53375117 | Quantitative RT-PCR assay for MUC3 and VEGF mRNA in renal clear cell carcinoma: relationship with nuclear grade and prognosis. |
| Q40840170 | Ribozyme approach to downregulate vascular endothelial growth factor (VEGF) 189 expression in non-small cell lung cancer (NSCLC). |
| Q36621890 | Ribozyme-mediated inactivation of mutant K-ras oncogene in a colon cancer cell line |
| Q35181953 | Role of VEGF in kidney development, microvascular maintenance and pathophysiology of renal disease |
| Q33587610 | Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas |
| Q39466387 | Suppression of vascular endothelial growth factor via siRNA interference modulates the biological behavior of human nasopharyngeal carcinoma cells |
| Q33955367 | The role of angiogenesis in prostate and other urologic cancers: a review |
| Q37458553 | The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts |
| Q46933593 | Translational research in renal cell cancer. Illustrated by the example of the vascular endothelial growth factor pathway |
| Q43739592 | Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma |
| Q58352361 | Tumour vascular endothelial growth factor (VEGF) mRNA in relation to serum VEGF protein levels and tumour progression in human renal cell carcinoma |
| Q38637013 | Unconventional Functions of Mitotic Kinases in Kidney Tumorigenesis |
| Q33307398 | VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma. |
| Q34406737 | VEGF-targeted therapy in metastatic renal cell carcinoma |
| Q34733006 | VEGF/VEGFR2 and PDGF-B/PDGFR-β expression in non-metastatic renal cell carcinoma: a retrospective study in 1,091 consecutive patients |
| Q35332976 | VEGFR-1 Expression Relates to Fuhrman Nuclear Grade of Clear Cell Renal Cell Carcinoma |
| Q28201021 | Vascular endothelial growth factor (VEGF) expression in the subacromial bursa is increased in patients with impingement syndrome |
| Q28209058 | Vascular endothelial growth factor 121 and 165 in the subacromial bursa are involved in shoulder joint contracture in type II diabetics with rotator cuff disease |
| Q45861347 | Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer |
| Q80295544 | [Is tumour expression of VEGF associated with venous invasion and survival in pT3 renal cell carcinoma?] |
Search more.